Literature DB >> 22176626

Immunosuppression, generic drugs and the FDA.

J Trofe-Clark, S Gabardi, L McDevitt-Potter, R R Alloway.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22176626     DOI： 10.1111/j.1600-6143.2011.03875.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN： 1600-6135            Impact factor:   8.086


× No keyword cloud information.
  3 in total

1.  A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients.

Authors:  R R Alloway; B Sadaka; J Trofe-Clark; A Wiland; R D Bloom
Journal:  Am J Transplant       Date:  2012-07-03       Impact factor: 8.086

2.  The Association of Tacrolimus Formulation Switching with Trough Concentration Variability: A Retrospective Cohort Study of Tacrolimus Use Post-Kidney Transplantation Based on National Drug Code (NDC) Numbers.

Authors:  Jason J Schwartz; Edward Lee; Ashley P Butler; David P Facklam; Billy Franks; James R Spalding; Maria E Vassilakis; Gary D Thal; William D Irish
Journal:  Adv Ther       Date:  2019-04-19       Impact factor: 3.845

Review 3.  Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis.

Authors:  Amber O Molnar; Dean Fergusson; Anne K Tsampalieros; Alexandria Bennett; Nicholas Fergusson; Timothy Ramsay; Greg A Knoll
Journal:  BMJ       Date:  2015-06-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.